Ionis Pharmaceuticals, Inc. has licensed IONIS-DNM2-2.5Rx, a drug that treats centronuclear myopathy (CNM), to Dynacure.    Ionis earned a $5 million license fee in the form of Dynacure equity from the agreement, and is eligible to receive additional cash or equity of up to more than $205 million in milestone payments. They also now have the eligibility to receive royalties on future product sales of the drug.   The collaboration also means that Dynacure will now assume all devel...